title: The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease.
abstract: The evidence supporting a treatment benefit for coenzyme Q10 (CoQ10) in primary mitochondrial disease (mitochondrial disease) whilst positive is limited. Mitochondrial disease in this context is defined as genetic disease causing an impairment in mitochondrial oxidative phosphorylation (OXPHOS). There are no treatment trials achieving the highest Level I evidence designation. Reasons for this include the relative rarity of mitochondrial disease, the heterogeneity of mitochondrial disease, the natural cofactor status and easy 'over the counter availability' of CoQ10 all of which make funding for the necessary large blinded clinical trials unlikely. At this time the best evidence for efficacy comes from controlled trials in common cardiovascular and neurodegenerative diseases with mitochondrial and OXPHOS dysfunction the etiology of which is most likely multifactorial with environmental factors playing on a background of genetic predisposition. There remain questions about dosing, bioavailability, tissue penetration and intracellular distribution of orally administered CoQ10, a compound which is endogenously produced within the mitochondria of all cells. In some mitochondrial diseases and other commoner disorders such as cardiac disease and Parkinson's disease low mitochondrial or tissue levels of CoQ10 have been demonstrated providing an obvious rationale for supplementation. This paper discusses the current state of the evidence supporting the use of CoQ10 in mitochondrial disease.
authors.affiliation: Department of Neurosciences, UCSD Mitochondrial and Metabolic Disease Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0935, USA. rhaas@ucsd.edu
authors.forename: Richard H
authors.initials: RH
authors.lastname: Haas
mesh_terms: D000818:Animals; D000975:Antioxidants; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism; D003067:Coenzymes / Q000737:chemistry / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006168:Guinea Pigs; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D028361:Mitochondrial Diseases / Q000188:drug therapy* / Q000378:metabolism*; D008954:Models, Biological; D010085:Oxidative Phosphorylation; D010100:Oxygen / Q000378:metabolism*; D010766:Phosphorylation; D051381:Rats; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10; D010100:Oxygen